Clinical Characteristics and Risk Factors of Respiratory Failure in a Cohort of Young Patients Requiring Hospital Admission with SARS-CoV2 Infection in Spain: Results of the Multicenter SEMI-COVID-19 Registry.


Journal

Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834

Informations de publication

Date de publication:
10 2021
Historique:
received: 19 03 2021
accepted: 21 07 2021
pubmed: 12 8 2021
medline: 5 10 2021
entrez: 11 8 2021
Statut: ppublish

Résumé

Age is a risk factor for COVID severity. Most studies performed in hospitalized patients with SARS-CoV2 infection have shown an over-representation of older patients and consequently few have properly defined COVID-19 in younger patients who require hospital admission. The aim of the present study was to analyze the clinical characteristics and risk factors for the development of respiratory failure among young (18 to 50 years) hospitalized patients with COVID-19. This retrospective nationwide cohort study included hospitalized patients from 18 to 50 years old with confirmed COVID-19 between March 1, 2020, and July 2, 2020. All patient data were obtained from the SEMI-COVID Registry. Respiratory failure was defined as the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2 ratio) ≤200 mmHg or the need for mechanical ventilation and/or high-flow nasal cannula or the presence of acute respiratory distress syndrome. During the recruitment period, 15,034 patients were included in the SEMI-COVID-19 Registry, of whom 2327 (15.4%) were younger than 50 years. Respiratory failure developed in 343 (14.7%), while mortality occurred in 2.3%. Patients with respiratory failure showed a higher incidence of major adverse cardiac events (44 (13%) vs 14 (0.8%), p<0.001), venous thrombosis (23 (6.7%) vs 14 (0.8%), p<0.001), mortality (43 (12.5%) vs 7 (0.4%), p<0.001), and longer hospital stay (15 (9-24) vs 6 (4-9), p<0.001), than the remaining patients. In multivariate analysis, variables associated with the development of respiratory failure were obesity (odds ratio (OR), 2.42; 95% confidence interval (95% CI), 1.71 to 3.43; p<0.0001), alcohol abuse (OR, 2.40; 95% CI, 1.26 to 4.58; p=0.0076), sleep apnea syndrome (SAHS) (OR, 2.22; 95% CI, 1.07 to 3.43; p=0.032), Charlson index ≥1 (OR, 1.77; 95% CI, 1.25 to 2.52; p=0.0013), fever (OR, 1.58; 95% CI, 1.13 to 2.22; p=0.0075), lymphocytes ≤1100 cells/μL (OR, 1.67; 95% CI, 1.18 to 2.37; p=0.0033), LDH >320 U/I (OR, 1.69; 95% CI, 1.18 to 2.42; p=0.0039), AST >35 mg/dL (OR, 1.74; 95% CI, 1.2 to 2.52; p=0.003), sodium <135 mmol/L (OR, 2.32; 95% CI, 1.24 to 4.33; p=0.0079), and C-reactive protein >8 mg/dL (OR, 2.42; 95% CI, 1.72 to 3.41; p<0.0001). Young patients with COVID-19 requiring hospital admission showed a notable incidence of respiratory failure. Obesity, SAHS, alcohol abuse, and certain laboratory parameters were independently associated with the development of this complication. Patients who suffered respiratory failure had a higher mortality and a higher incidence of major cardiac events, venous thrombosis, and hospital stay.

Sections du résumé

BACKGROUND
Age is a risk factor for COVID severity. Most studies performed in hospitalized patients with SARS-CoV2 infection have shown an over-representation of older patients and consequently few have properly defined COVID-19 in younger patients who require hospital admission. The aim of the present study was to analyze the clinical characteristics and risk factors for the development of respiratory failure among young (18 to 50 years) hospitalized patients with COVID-19.
METHODS
This retrospective nationwide cohort study included hospitalized patients from 18 to 50 years old with confirmed COVID-19 between March 1, 2020, and July 2, 2020. All patient data were obtained from the SEMI-COVID Registry. Respiratory failure was defined as the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2 ratio) ≤200 mmHg or the need for mechanical ventilation and/or high-flow nasal cannula or the presence of acute respiratory distress syndrome.
RESULTS
During the recruitment period, 15,034 patients were included in the SEMI-COVID-19 Registry, of whom 2327 (15.4%) were younger than 50 years. Respiratory failure developed in 343 (14.7%), while mortality occurred in 2.3%. Patients with respiratory failure showed a higher incidence of major adverse cardiac events (44 (13%) vs 14 (0.8%), p<0.001), venous thrombosis (23 (6.7%) vs 14 (0.8%), p<0.001), mortality (43 (12.5%) vs 7 (0.4%), p<0.001), and longer hospital stay (15 (9-24) vs 6 (4-9), p<0.001), than the remaining patients. In multivariate analysis, variables associated with the development of respiratory failure were obesity (odds ratio (OR), 2.42; 95% confidence interval (95% CI), 1.71 to 3.43; p<0.0001), alcohol abuse (OR, 2.40; 95% CI, 1.26 to 4.58; p=0.0076), sleep apnea syndrome (SAHS) (OR, 2.22; 95% CI, 1.07 to 3.43; p=0.032), Charlson index ≥1 (OR, 1.77; 95% CI, 1.25 to 2.52; p=0.0013), fever (OR, 1.58; 95% CI, 1.13 to 2.22; p=0.0075), lymphocytes ≤1100 cells/μL (OR, 1.67; 95% CI, 1.18 to 2.37; p=0.0033), LDH >320 U/I (OR, 1.69; 95% CI, 1.18 to 2.42; p=0.0039), AST >35 mg/dL (OR, 1.74; 95% CI, 1.2 to 2.52; p=0.003), sodium <135 mmol/L (OR, 2.32; 95% CI, 1.24 to 4.33; p=0.0079), and C-reactive protein >8 mg/dL (OR, 2.42; 95% CI, 1.72 to 3.41; p<0.0001).
CONCLUSIONS
Young patients with COVID-19 requiring hospital admission showed a notable incidence of respiratory failure. Obesity, SAHS, alcohol abuse, and certain laboratory parameters were independently associated with the development of this complication. Patients who suffered respiratory failure had a higher mortality and a higher incidence of major cardiac events, venous thrombosis, and hospital stay.

Identifiants

pubmed: 34379281
doi: 10.1007/s11606-021-07066-z
pii: 10.1007/s11606-021-07066-z
pmc: PMC8356682
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3080-3087

Informations de copyright

© 2021. Society of General Internal Medicine.

Références

Ann Emerg Med. 2020 Oct;76(4):442-453
pubmed: 33012378
Chest. 2007 Aug;132(2):410-7
pubmed: 17573487
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Clin Interv Aging. 2020 Nov 09;15:2095-2107
pubmed: 33204075
Lancet Public Health. 2020 Aug;5(8):e444-e451
pubmed: 32619408
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Clin Ther. 2020 Jun;42(6):964-972
pubmed: 32362344
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):e28-e37
pubmed: 33103720
Heart. 2021 Mar;107(5):373-380
pubmed: 33334865
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Clin Microbiol Infect. 2020 Nov;26(11):1545-1553
pubmed: 32781244
EClinicalMedicine. 2020 Jul 03;24:100426
pubmed: 32766541
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA Intern Med. 2020 Sep 9;:
pubmed: 32902580
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Rev Clin Esp. 2020 Nov;220(8):480-494
pubmed: 33994573
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
JAMA. 2021 Jan 12;325(2):123-124
pubmed: 33331845
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1517-1521
pubmed: 33090984
Chest. 2020 Jul;158(1):97-105
pubmed: 32304772
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797

Auteurs

Raquel Díaz-Simón (R)

Internal Medicine Department, 12 de Octubre University Hospital, Madrid, Spain. rdiazs@salud.madrid.org.

Antonio Lalueza (A)

Internal Medicine Department, 12 de Octubre University Hospital, Madrid, Spain.

Jaime Lora-Tamayo (J)

Internal Medicine Department, 12 de Octubre University Hospital, Madrid, Spain.

Manuel Rubio-Rivas (M)

Internal Medicine Department, Bellvitge L'Hospitalet de Llobregat University Hospital, Barcelona, Spain.

Cristina Llamazares Mendo (CL)

Internal Medicine Department, Gregorio Marañon University Hospital, Madrid, Spain.

María Luisa Taboada Martínez (MLT)

Internal Medicine Department, Cabueñes Hospital, (Asturias), Gijón, Spain.

Cristina Asencio Méndez (CA)

Internal Medicine Department, Costa del Sol Hospital, (Málaga), Marbella, Spain.

Paula M Pesqueira Fontán (PM)

Internal Medicine Department, Clinic Santiago de Compostela Hospital, A Coruña, Spain.

Ana Fernández Cruz (AF)

Internal Medicine Department, Puerta de Hierro University Hospital, (Madrid), Majadahonda, Spain.

Juan Luis Romero Cabrera (JLR)

Internal Medicine Department, Reina Sofía University Hospital, Córdoba, Spain.

Begoña Cortés Rodríguez (BC)

Internal Medicine Department, Alto Guadalquivir Hospital, (Jaén), Andújar, Spain.

Aurora Espinar Rubio (AE)

Internal Medicine Department, Juan Ramón Jiménez Hospital, Huelva, Spain.

Vicente Serrano Romero de Ávila (VSR)

Internal Medicine Department, Virgen de la Salud Hospital, Toledo, Spain.

Gema Maria García García (GMG)

Internal Medicine Department, Badajoz University Hospital Complex, Badajoz, Spain.

Luis Cabeza Osorio (LC)

Internal Medicine Department, Henares Hospital, (Madrid), Coslada, Spain.

María González-Fernández (M)

Internal Medicine Department, Rio Ortega University Hospital, Valladolid, Spain.

Amara González Noya (AG)

Internal Medicine Department, Ourense University Hospital Complex, Ourense, Spain.

Máximo Bernabeu Wittel (MB)

Internal Medicine Department, Virgen del Rocío University Hospital, Sevilla, Spain.

Francisco Arnalich Fernandez (FA)

Internal Medicine Department, La Paz/Carlos III/Cantoblanco University Hospital, Madrid, Spain.

Verónica Martínez Sempere (VM)

Internal Medicine Department, S. Juan de Alicante University Hospital, Alicante, Spain.

Arturo Artero (A)

Internal Medicine Department, Dr. Peset University Hospital, Valencia, Spain.

Jose Loureiro-Amigo (J)

Internal Medicine Department, Moisès Broggi Sant Joan Despí Hospital, Barcelona, Spain.

Ricardo Gómez Huelgas (RG)

Internal Medicine Department, Málaga Regional University Hospital, Malaga, Spain.

Juan Miguel Antón Santos (JMA)

Internal Medicine Department, Infanta Cristina University Hospital, (Madrid), Parla, Spain.

Carlos Lumbreras (C)

Internal Medicine Department, 12 de Octubre University Hospital, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH